

Philip S Helliwell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4385667/philip-s-helliwell-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

9,050
citations

45
h-index

91
g-index

232
ext. papers

10,941
ext. citations

5.1
avg. IF

6.24
L-index

#	Paper	IF	Citations
186	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 40	5.7	1
185	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial. <i>Lancet Rheumatology, The</i> , 2022 , 4, e252-e261	14.2	1
184	Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'? by Braun and Landewé <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	1
183	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211057975	3.8	1
182	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 836-840	4.1	2
181	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021 ,	4.1	4
180	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021 , 23, 94	5.7	2
179	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021 ,	4.1	3
178	Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives. <i>Frontiers in Immunology</i> , 2021 , 12, 614653	8.4	1
177	Development of an Instrument for Patient Self-assessment in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1680-1685	4.1	
176	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1815-1823	4.1	3
175	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaire-Disability Index. <i>Journal of Rheumatology</i> , 2021 , 48, 1686-1691	4.1	0
174	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. <i>BMC Rheumatology</i> , 2021 , 5, 19	2.9	1
173	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , 2021 , 73, 856-860	4.7	17
172	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 185-193	2.4	26
171	A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. <i>Rheumatology</i> , 2021 , 60, 340-345	3.9	2
170	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021 , 60, 1137-1147	3.9	7

169	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	6
168	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021 , 48, 1268-1271	4.1	1
167	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF inhibitor-experienced. <i>RMD Open</i> , 2021 , 7,	5.9	10
166	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. <i>Clinical Trials</i> , 2021 , 18, 541-551	2.2	
165	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology, The</i> , 2021 , 3, e715-e723	14.2	14
164	Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNF inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1115-1125	40	93
163	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020 , 59, 2774-2784	3.9	12
162	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , 2020 , 6,	5.9	17
161	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). <i>Trials</i> , 2020 , 21, 155	2.8	4
160	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020 , 96, 53-57	4.1	6
159	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020 , 47, 1338-1343	4.1	5
158	Axial disease in psoriatic arthritis. <i>Rheumatology</i> , 2020 , 59, 1193-1195	3.9	14
157	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 123-131	2.4	116
156	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa032	1.1	1
155	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa043	1.1	
154	The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians. <i>Rheumatology and Therapy</i> , 2020 , 7, 883-891	4.4	6
153	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020 , 6,	5.9	12
152	P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PSA who were biologic-naïve or prior TNF inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2020 , 59,	3.9	1

151	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020 , 2, 543-554	3.5	2
150	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020 , 72, 1579-1588	4.7	4
149	Long-term follow-up of patients in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020 , 59, 807-810	3.9	4
148	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. <i>Rheumatology and Therapy</i> , 2019 , 6, 521-528	4.4	7
147	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019 , 95, 54-57	4.1	6
146	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1112-1124	9.5	94
145	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019 , 46, 38-42	4.1	16
144	Pathophysiology, assessment and treatment of psoriatic dactylitis. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 113-122	8.1	29
143	Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. <i>Rheumatology and Therapy</i> , 2019 , 6, 23-32	4.4	24
142	Verna Wright: father of the spondyloarthropathies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 454-455	2.4	1
141	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1530-1534	4.6	11
140	Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 467-468	2.4	14
139	Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018 , 70, 462-468	4.7	11
138	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
137	Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. <i>Arthritis Care and Research</i> , 2018 , 70, 797-800	4.7	9
136	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 654-665	5.3	32
135	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 719-730	5.1	48
134	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. <i>BMC Rheumatology</i> , 2018 , 2, 24	2.9	12

133	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018 , 45, 1256-1262	4.1	6
132	Werner syndrome: a rare cause of osteoporosis in a young female. <i>Rheumatology</i> , 2018 , 57, 2021	3.9	1
131	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
130	Focussing on the foot in psoriatic arthritis: pathology and management options. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 21-28	5.1	10
129	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018 , 70, 1198-1205	4.7	22
128	Current concepts and unmet needs in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018 , 37, 297-305	3.9	17
127	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018 , 20, 242	5.7	17
126	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 2367-2377	4.0	107
125	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 1700-1705	4.7	10
124	Psoriatic arthritis: state of the art review. <i>Clinical Medicine</i> , 2017 , 17, 65-70	1.9	99
123	Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?. <i>Rheumatology and Therapy</i> , 2017 , 4, 71-84	4.4	14
122	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017 , 44, 706-710	4.1	1
121	Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 674-678	4.1	15
120	La fatigue dans le rhumatisme psoriasique. Etude transversale portant sur 246 patients de 13 pays. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 321-325	0.1	
119	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1688-1692	2.4	15
118	Que signifie l'évaluation globale par le patient dans le rhumatisme psoriasique? Une analyse de 223 patients issus de l'étude d'évaluation du Psoriatic Arthritis Impact of Disease (PsAID). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 314-320	0.1	
117	An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. <i>Clinical Rheumatology</i> , 2017 , 36, 719-723	3.9	1
116	The GOLMePSA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 303	2.8	8

115	Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 308	2.8	6
114	Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. <i>Clinical Rheumatology</i> , 2017 , 36, 1803-1810	3.9	
113	Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. <i>Rheumatology</i> , 2017 , 56, 603-612	3.9	15
112	The NICE appraisal of ustekinumab for treating psoriatic arthritis. <i>British Journal of Health Care Management</i> , 2016 , 22, 68-71	0.4	1
111	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. <i>Rheumatology</i> , 2016 , 55, 2277-2278	3.9	11
110	More than meets the eye?. <i>Lancet, The</i> , 2016 , 388, e15	4.0	
109	Plantar forefoot pressures in psoriatic arthritis-related dactylitis: an exploratory study. <i>Clinical Rheumatology</i> , 2016 , 35, 2333-8	3.9	15
108	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 965-9	4.1	22
107	A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2016 , 35, 2967-2974	3.9	9
106	L.C. Coates and P.S. Helliwell reply. <i>Journal of Rheumatology</i> , 2016 , 43, 1766	4.1	
105	Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1417-8	2.4	5
104	Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 986-9	4.1	0
103	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016 , 43, 979-85	4.1	2
102	Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016 , 83, 439-43	2.9	40
101	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016 , 3, 91-102	4.4	92
100	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 291-304	5.3	84
99	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
98	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. <i>British Journal of Dermatology</i> , 2016 , 175, 542-8	4	15

97	Foot orthoses in the treatment of symptomatic midfoot osteoarthritis using clinical and biomechanical outcomes: a randomised feasibility study. <i>Clinical Rheumatology</i> , 2016 , 35, 987-96	3.9	26
96	Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. <i>Journal of Rheumatology</i> , 2016 , 43, 356-61	4.1	65
95	Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. <i>Journal of Rheumatology</i> , 2016 , 43, 371-5	4.1	65
94	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2016 , 68, 267-74	4.7	57
93	Psoriasis flare with corticosteroid use in psoriatic arthritis. <i>British Journal of Dermatology</i> , 2016 , 174, 219-21	4	11
92	Treating to target in psoriatic arthritis: how to implement in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 640-3	2.4	30
91	Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016 , 83, 335-40	2.9	28
90	Interpreting outcome following foot surgery in people with rheumatoid arthritis. <i>Journal of Foot and Ankle Research</i> , 2016 , 9, 20	3.2	2
89	Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 974-8	4.1	11
88	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015 , 42, 2198-203	4.1	29
87	Interleukin-17 inhibition in psoriatic arthritis. <i>Lancet, The</i> , 2015 , 386, 1114-6	4.0	4
86	Treat to target in psoriatic arthritis-evidence, target, research agenda. <i>Current Rheumatology Reports</i> , 2015 , 17, 517	4.9	12
85	Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , 2015 , 2, 1-16	4.4	26
84	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 2489-98	4.0	271
83	Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 581-91	2.4	16
82	The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e66	2.4	7
81	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103
80	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. <i>Rheumatology</i> , 2015 , 54, 157-62	3.9	46

79	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. <i>Rheumatology</i> , 2015 , 54, 200-2	3.9	7
78	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1041-1043	4.1	2
77	It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. <i>Rheumatology</i> , 2015 , 54, 1448-53	3.9	27
76	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1882-5	2.4	49
75	A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic Arthritis (RETREAT (F))). <i>Clinical Rheumatology</i> , 2015 , 34, 1407-12	3.9	18
74	Assessment of disease activity in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S44-7	2.2	24
73	The predictors of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014 , 33, 615-21	3.9	8
72	Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. <i>Arthritis Care and Research</i> , 2014 , 66, 749-56	4.7	48
71	Comprehensive treatment of dactylitis in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2295-300	4.1	37
70	Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. <i>Journal of Rheumatology</i> , 2014 , 41, 2277-85	4.1	38
69	Psoriasis and psoriatic arthritis educational initiatives: an update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1240-3	4.1	7
68	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 649-55	4.5	42
67	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1012-9	2.4	200
66	Patient involvement in outcome measures for psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 418	4.9	27
65	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
64	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2014 , 383, S36	4.0	14
63	Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. <i>Clinical Biomechanics</i> , 2014 , 29, 811-4	2.2	5
62	Aiming for remission in psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 147-153	3.5	1

61	Qualifying unmet needs and improving standards of care in psoriatic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1759-66	4.7	57
60	I58. Therapy of PSA: What is New and How Can We Treat to Target?. <i>Rheumatology</i> , 2014 , 53, i13-i13	3.9	
59	Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1249-51	4.1	23
58	Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014 , 41, 782-91	4.1	30
57	GRAPPA 2013 Annual Meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project. <i>Journal of Rheumatology</i> , 2014 , 41, 1244-8	4.1	5
56	Is there subclinical synovitis in early psoriatic arthritis? A clinical comparison with gray-scale and power Doppler ultrasound. <i>Arthritis Care and Research</i> , 2014 , 66, 432-9	4.7	64
55	Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. <i>Arthritis Care and Research</i> , 2014 , 66, 1410-6	4.7	18
54	Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. <i>Dermatology and Therapy</i> , 2013 , 3, 1-15	4	80
53	The TICOPA protocol (Tight Control of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 101	2.8	83
52	Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised controlled trial. <i>Clinical Rheumatology</i> , 2013 , 32, 567-74	3.9	24
51	Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1504-9		52
50	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 986-91	2.4	192
49	A case series to describe the clinical characteristics of foot ulceration in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2012 , 31, 541-5	3.9	12
48	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 358-62	2.4	52
47	Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3150-5		66
46	GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2196-7	4.1	7
45	Magnetic resonance arthrography of lesser metatarsophalangeal joints in patients with rheumatoid arthritis: relationship to clinical, biomechanical, and radiographic variables. <i>Journal of Rheumatology</i> , 2012 , 39, 1786-91	4.1	12
44	Remission in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 19-21		11

43	The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Index Project (GRACE). <i>Psoriasis Forum</i> , 2011 , 17a, 216-219		
42	Joint orthopaedic and rheumatology clinics: evidence to support the guidelines. <i>Musculoskeletal Care</i> , 2011 , 9, 180-3	1.6	4
41	Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 551-2	4.1	24
40	Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011 , 50, 1586-95	3.9	16
39	Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 540-5	4.1	21
38	Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. <i>Journal of Rheumatology</i> , 2011 , 38, 1496-501	4.1	30
37	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 272-7	2.4	133
36	Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. <i>Journal of Rheumatology</i> , 2011 , 38, 898-903	4.1	82
35	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010 , 49, 1793-4; author reply 1794	3.9	4
34	Development of screening tools to identify psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2010 , 12, 295-9	4.9	23
33	Disease measurement--enthesitis, skin, nails, spine and dactylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 659-70	5.3	25
32	Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. <i>Arthritis Care and Research</i> , 2010 , 62, 965-9	4.7	161
31	Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 1006-11	4.1	37
30	Established psoriatic arthritis: clinical aspects. <i>Journal of rheumatology Supplement, The</i> , 2009 , 83, 21-3		15
29	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1235-42		83
28	The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. <i>Journal of Clinical Rheumatology</i> , 2009 , 15, 223-5	1.1	12
27	Biomechanics of the foot in rheumatoid arthritis: Identifying abnormal function and the factors that predict disease impact. <i>Clinical Biomechanics</i> , 2008 , 23, 719-720	2.2	
26	The predictors of foot ulceration in patients with rheumatoid arthritis: a preliminary investigation. <i>Clinical Rheumatology</i> , 2008 , 27, 1423-8	3.9	18

25	Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 686-91		247
24	Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. <i>Journal of Rheumatology</i> , 2008 , 35, 472-6	4.1	44
23	Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. <i>Journal of Rheumatology</i> , 2008 , 35, 1359-61	4.1	16
22	Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. <i>Journal of Rheumatology</i> , 2008 , 35, 1438-42	4.1	27
21	Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial. <i>BMC Musculoskeletal Disorders</i> , 2007 , 8, 109	2.8	13
20	Measuring dactylitis in clinical trials: which is the best instrument to use?. <i>Journal of Rheumatology</i> , 2007 , 34, 1302-6	4.1	48
19	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70	4.1	144
18	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007 , 34, 1733-9	4.1	48
17	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1740-5	4.1	67
16	Dactylitis: pathogenesis and clinical considerations. <i>Current Rheumatology Reports</i> , 2006 , 8, 338-41	4.9	24
15	The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series. <i>BMC Musculoskeletal Disorders</i> , 2006 , 7, 102	2.8	90
14	Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2665-73		2136
13	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". <i>Journal of Rheumatology</i> , 2006 , 33, 552-7	4.1	11
12	Therapies for dactylitis in psoriatic arthritis. A systematic review. <i>Journal of Rheumatology</i> , 2006 , 33, 1439-41	4.1	23
11	Classification of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 395-9	5.3	33
10	Development of a foot impact scale for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 53, 418-22		96
9	Development of an assessment tool for dactylitis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1745-50	4.1	84
8	Outcome measures in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 2262-9	4.1	33

7	A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004 , 34, 575-84	5.3	76
6	Development of diagnostic criteria for psoriatic arthritis: methods and process. <i>Current Rheumatology Reports</i> , 2004 , 6, 299-305	4.9	17
5	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004 , 50, 24-35		151
4	Relationship of psoriatic arthritis with the other spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 344-9	5.3	17
3	A randomized controlled trial of foot orthoses in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002 , 29, 1377-83	4.1	115
2	Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: comment on the article by Clegg et al. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1911-2		2
1	Human nocturnal blood melatonin and liver acetylation status. <i>Journal of Pineal Research</i> , 1991 , 10, 14-710.4		3